{"entity":{"type":"insider","cik":"0001299153","url":"/insider/0001299153","json_url":"/insider/0001299153.json","name":"ANDREWS RONALD ASBURY","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":14,"first":"2004-08-10","last":"2022-08-18","span_basis":"filed_date"},"name_variants":[{"name":"ANDREWS RONALD ASBURY","source":"filing","n_filings":8,"first_seen":"2012-05-01","last_seen":"2022-08-18"},{"name":"Andrews Ronald Asbury","source":"filing","n_filings":6,"first_seen":"2004-08-10","last_seen":"2010-03-15"}],"transactions":[{"id":6726209,"accession":"0001493152-22-023462","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-023462","line_url":"/filing/0001493152-22-023462#line-1","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"Oncocyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (President & CEO)","officer_title":"President & CEO","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":0.96,"price_display":"0.96","price_state":"stated","total_value":38400.0,"total_display":"38,400.00","shares_owned_after":333212.0,"shares_owned_after_display":"333,212","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-16","filed_date":"2022-08-18","scope":"insider"},{"id":6514082,"accession":"0001493152-22-007205","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-22-007205","line_url":"/filing/0001493152-22-007205#line-1","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"Oncocyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":1.283,"price_display":"1.28","price_state":"stated","total_value":64150.0,"total_display":"64,150.00","shares_owned_after":293212.0,"shares_owned_after_display":"293,212","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-16","filed_date":"2022-03-17","scope":"insider"},{"id":4420232,"accession":"0001493152-21-006546","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-21-006546","line_url":"/filing/0001493152-21-006546#line-1","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11000.0,"shares_display":"11,000","price_per_share":4.7911,"price_display":"4.79","price_state":"stated","total_value":52702.1,"total_display":"52,702.10","shares_owned_after":113698.0,"shares_owned_after_display":"113,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-19","filed_date":"2021-03-22","scope":"insider"},{"id":2610509,"accession":"0001493152-20-014613","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-014613","line_url":"/filing/0001493152-20-014613#line-1","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (Chief Executive Officer)","officer_title":"Chief Executive Officer","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40000.0,"shares_display":"40,000","price_per_share":1.347,"price_display":"1.35","price_state":"stated","total_value":53880.0,"total_display":"53,880.00","shares_owned_after":102698.0,"shares_owned_after_display":"102,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-03","filed_date":"2020-08-04","scope":"insider"},{"id":9290065,"accession":"0001493152-20-005646","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-20-005646","line_url":"/filing/0001493152-20-005646#line-2","is_derivative":false,"issuer_cik":"0001642380","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001642380","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (CEO and President)","officer_title":"CEO and President","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18000.0,"shares_display":"18,000","price_per_share":2.372,"price_display":"2.37","price_state":"stated","total_value":42696.0,"total_display":"42,696.00","shares_owned_after":62698.0,"shares_owned_after_display":"62,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-31","filed_date":"2020-04-01","scope":"insider"},{"id":2237577,"accession":"0001493152-20-005608","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001493152-20-005608","line_url":"/filing/0001493152-20-005608#line-2","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (CEO and President)","officer_title":"CEO and President","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18000.0,"shares_display":"18,000","price_per_share":2372.0,"price_display":"2,372.00","price_state":"stated","total_value":42696000.0,"total_display":"42,696,000.00","shares_owned_after":62698.0,"shares_owned_after_display":"62,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-31","filed_date":"2020-04-01","scope":"insider"},{"id":9290064,"accession":"0001493152-20-005646","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-005646","line_url":"/filing/0001493152-20-005646#line-1","is_derivative":false,"issuer_cik":"0001642380","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001642380","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (CEO and President)","officer_title":"CEO and President","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27216.0,"shares_display":"27,216","price_per_share":2.258,"price_display":"2.26","price_state":"stated","total_value":61453.728,"total_display":"61,453.73","shares_owned_after":44698.0,"shares_owned_after_display":"44,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-30","filed_date":"2020-04-01","scope":"insider"},{"id":2237572,"accession":"0001493152-20-005608","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-20-005608","line_url":"/filing/0001493152-20-005608#line-1","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director, Officer (CEO and President)","officer_title":"CEO and President","security_title":"Common Stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27216.0,"shares_display":"27,216","price_per_share":2.258,"price_display":"2.26","price_state":"stated","total_value":61453.728,"total_display":"61,453.73","shares_owned_after":44698.0,"shares_owned_after_display":"44,698","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-03-30","filed_date":"2020-04-01","scope":"insider"},{"id":5973788,"accession":"0001493152-18-010765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001493152-18-010765","line_url":"/filing/0001493152-18-010765#line-1","is_derivative":false,"issuer_cik":"0001299153","issuer_name":"OncoCyte Corp","issuer_ticker":"OCX","issuer_name_source":null,"issuer_url":"/issuer/0001299153","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Director","officer_title":null,"security_title":"Common stock, no par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":17482.0,"shares_display":"17,482","price_per_share":null,"price_display":null,"price_state":"not-stated","total_value":null,"total_display":null,"shares_owned_after":17482.0,"shares_owned_after_display":"17,482","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-26","filed_date":"2018-07-31","scope":"insider"},{"id":2454894,"accession":"0001127602-12-015241","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001127602-12-015241","line_url":"/filing/0001127602-12-015241#line-1","is_derivative":false,"issuer_cik":"0001073431","issuer_name":"Life Technologies Corp","issuer_ticker":"LIFE","issuer_name_source":null,"issuer_url":"/issuer/0001073431","owner_cik":"0001299153","owner_name":"ANDREWS RONALD ASBURY","owner_url":"/insider/0001299153","role":"Officer (President, Medical Sciences)","officer_title":"President, Medical Sciences","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3330.0,"shares_display":"3,330","price_per_share":46.4907,"price_display":"46.49","price_state":"stated","total_value":154814.031,"total_display":"154,814.03","shares_owned_after":3330.0,"shares_owned_after_display":"3,330","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-04-27","filed_date":"2012-05-01","scope":"insider"},{"id":7584565,"accession":"0001179110-10-005205","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-10-005205","line_url":"/filing/0001179110-10-005205#line-1","is_derivative":false,"issuer_cik":"0001038223","issuer_name":"CLARIENT, INC","issuer_ticker":"CLRT","issuer_name_source":null,"issuer_url":"/issuer/0001038223","owner_cik":"0001299153","owner_name":"Andrews Ronald Asbury","owner_url":"/insider/0001299153","role":"Director, Officer (Vice-Chairman and CEO)","officer_title":"Vice-Chairman and CEO","security_title":"Clarient Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":2.41,"price_display":"2.41","price_state":"stated","total_value":28920.0,"total_display":"28,920.00","shares_owned_after":72500.0,"shares_owned_after_display":"72,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2010-03-12","filed_date":"2010-03-15","scope":"insider"},{"id":3469827,"accession":"0000086115-08-000059","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000086115-08-000059","line_url":"/filing/0000086115-08-000059#line-1","is_derivative":false,"issuer_cik":"0001038223","issuer_name":"CLARIENT, INC","issuer_ticker":"CLRT","issuer_name_source":null,"issuer_url":"/issuer/0001038223","owner_cik":"0001299153","owner_name":"Andrews Ronald Asbury","owner_url":"/insider/0001299153","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":1.9347,"price_display":"1.93","price_state":"stated","total_value":14510.25,"total_display":"14,510.25","shares_owned_after":60500.0,"shares_owned_after_display":"60,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-09-18","filed_date":"2008-09-19","scope":"insider"},{"id":7591212,"accession":"0001179110-07-009498","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001179110-07-009498","line_url":"/filing/0001179110-07-009498#line-1","is_derivative":false,"issuer_cik":"0001038223","issuer_name":"CLARIENT, INC","issuer_ticker":"CLRT","issuer_name_source":null,"issuer_url":"/issuer/0001038223","owner_cik":"0001299153","owner_name":"Andrews Ronald Asbury","owner_url":"/insider/0001299153","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":1.92,"price_display":"1.92","price_state":"stated","total_value":9600.0,"total_display":"9,600.00","shares_owned_after":53000.0,"shares_owned_after_display":"53,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2007-05-07","filed_date":"2007-05-08","scope":"insider"},{"id":1421711,"accession":"0001299153-05-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001299153-05-000005","line_url":"/filing/0001299153-05-000005#line-1","is_derivative":false,"issuer_cik":"0001038223","issuer_name":"CLARIENT, INC","issuer_ticker":"CLRT","issuer_name_source":null,"issuer_url":"/issuer/0001038223","owner_cik":"0001299153","owner_name":"Andrews Ronald Asbury","owner_url":"/insider/0001299153","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":1.188,"price_display":"1.19","price_state":"stated","total_value":11880.0,"total_display":"11,880.00","shares_owned_after":48000.0,"shares_owned_after_display":"48,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-11-14","filed_date":"2005-11-16","scope":"insider"},{"id":1677083,"accession":"0001299153-05-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001299153-05-000002","line_url":"/filing/0001299153-05-000002#line-1","is_derivative":false,"issuer_cik":"0001038223","issuer_name":"CHROMAVISION MEDICAL SYSTEMS INC","issuer_ticker":"CLRT","issuer_name_source":null,"issuer_url":"/issuer/0001038223","owner_cik":"0001299153","owner_name":"Andrews Ronald Asbury","owner_url":"/insider/0001299153","role":"Director, Officer (President and CEO)","officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18000.0,"shares_display":"18,000","price_per_share":1.4028,"price_display":"1.40","price_state":"stated","total_value":25250.4,"total_display":"25,250.40","shares_owned_after":38000.0,"shares_owned_after_display":"38,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2005-06-10","filed_date":"2005-06-16","scope":"insider"},{"id":668078,"accession":"0001299153-04-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001299153-04-000002","line_url":"/filing/0001299153-04-000002#line-1","is_derivative":false,"issuer_cik":"0001038223","issuer_name":"CHROMAVISION MEDICAL SYSTEMS INC","issuer_ticker":"CVSN","issuer_name_source":null,"issuer_url":"/issuer/0001038223","owner_cik":"0001299153","owner_name":"Andrews Ronald Asbury","owner_url":"/insider/0001299153","role":"Officer (President & CEO)","officer_title":"President & CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":1.15,"price_display":"1.15","price_state":"stated","total_value":23000.0,"total_display":"23,000.00","shares_owned_after":20000.0,"shares_owned_after_display":"20,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2004-08-06","filed_date":"2004-08-10","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":16,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001642380","name":"Oncocyte Corp","url":"/issuer/0001642380","role":"Director, Officer (President & CEO)","n_filings":7,"first_seen":"2018-07-31","last_seen":"2022-08-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001073431","name":"Life Technologies Corp","url":"/issuer/0001073431","role":"Officer (President, Medical Sciences)","n_filings":1,"first_seen":"2012-05-01","last_seen":"2012-05-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001038223","name":"CLARIENT, INC","url":"/issuer/0001038223","role":"Director, Officer (Vice-Chairman and CEO)","n_filings":6,"first_seen":"2004-08-10","last_seen":"2010-03-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001299153","retrieved_at":"2026-08-21T23:35:19+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}